Дата |
---|
28.03.2024 |
27.03.2024 |
26.03.2024 |
25.03.2024 |
18.03.2024 |
14.03.2024 |
13.03.2024 |
12.03.2024 |
11.03.2024 |
08.03.2024 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
---|---|---|---|---|---|---|---|
0.035
|
0.0678
|
0.0676
|
0.0676
|
0.0676
|
0.0676
|
|
|
80.92
|
1.00
|
0.035
|
0.099
|
0.05
|
0.0351
|
0.05
|
0.0351
|
|
|
96.77
|
12.00
|
0.05
|
0.0678
|
0.0569
|
0.05
|
0.0569
|
0.050155
|
|
|
252.05
|
8.00
|
0.05
|
0.0678
|
0.0569
|
0.0569
|
0.0569
|
0.0569
|
|
|
11.38
|
2.00
|
0.05
|
0.0678
|
0.06
|
0.0513
|
0.06
|
0.0513
|
|
|
698.25
|
3.00
|
0.05
|
0.0678
|
0.06259
|
0.06
|
0.06259
|
0.060001
|
|
|
290.61
|
7.00
|
0.06
|
0.0678
|
0.06
|
0.06
|
0.0678
|
0.0601
|
|
|
198.65
|
4.00
|
0.04
|
0.0678
|
0.0568
|
0.0568
|
0.0679
|
0.0601
|
|
|
955.78
|
31.00
|
0.0351
|
0.06
|
0.0568
|
0.035
|
0.0568
|
0.04
|
|
|
79.31
|
8.00
|
0.035
|
0.06
|
0.0598
|
0.0437
|
0.0598
|
0.0547
|
|
|
181.91
|
16.00
|
Biofrontera Inc. (Biofrontera) is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions. With a focus on the fields of photodynamic therapy (PDT) and topical antibiotics, Biofrontera currently commercializes the FDA-approved flagship drug Ameluz (aminolevulinic acid hydrochloride gel, 10%) in the United States. When used in combination with PDT and Biofrontera’s BF-RhodoLED lamp, Ameluz-PDT is indicated for the treatment of actinic keratoses (AK), one of the most common precancerous skin conditions. Biofrontera also commercializes the drug Xepi (ozenoxacin cream, 1%), FDA-approved for the treatment of impetigo.
In collaboration with dermatologists, Biofrontera is fully committed to advancing treatment options and patient care.
Показать все Скрыть